Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study

January 2025 in “ Journal of the European Academy of Dermatology and Venereology ”

Christos Tziotzios, Rodney Sinclair, Aleksandra Lesiak, Stephanie Mehlis, Misaki Kinoshita‐Ise, Athanasios Tsianakas, Xin Luo, Ernest H. Law, R. Ishowo‐Adejumo, Robert Wołk, Mojgan Sadrarhami, A. Lejeune

ritlecitinib alopecia areata SALT score eyebrow regrowth eyelash regrowth

TLDR Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

The ALLEGRO-LT phase 3 study assessed the long-term safety and efficacy of ritlecitinib in 447 patients aged 12 and older with alopecia areata and at least 25% scalp hair loss. Over 24 months, 73.5% of patients achieved a SALT score of ≤20, and 66.4% achieved ≤10, indicating significant hair regrowth. The study found higher response rates in patients with less extensive hair loss at baseline, suggesting early intervention may improve outcomes. Eyebrow and eyelash regrowth was also notable, with over 60% of patients showing improvement. The safety profile was consistent with previous reports, with mostly mild to moderate adverse events. The study highlights ritlecitinib as an effective and well-tolerated treatment for alopecia areata.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

25 / 25 results

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions

4 citations , November 2023 in “Frontiers in immunology”

New treatments targeting T-cell pathways are needed for better alopecia areata management.

research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

1 citations , September 2023 in “Dermatology and Therapy”

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study

September 2023 in “Dermatology and therapy”

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata

research The Relationship Between Patient-Reported Severity of Hair Loss and Health-Related Quality of Life and Treatment Patterns Among Patients with Alopecia Areata

4 citations , March 2022 in “Dermatology and Therapy”

People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review

67 citations , March 2021 in “Dermatology and Therapy”

Alopecia areata greatly harms quality of life, causing emotional and social issues.

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations , March 2021 in “Journal of the American Academy of Dermatology”

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan

research Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan

7 citations , January 2021 in “Dermatology and therapy”

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata

research ‘You Lose Your Hair, What’s the Big Deal?’ I Was So Embarrassed, I Was So Self-Conscious, I Was So Depressed: A Qualitative Interview Study to Understand the Psychosocial Burden of Alopecia Areata

30 citations , September 2020 in “Journal of Patient-Reported Outcomes”

Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.

research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata

134 citations , July 2020 in “Experimental dermatology”

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations , October 2019 in “Frontiers in Immunology”

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

53 citations , July 2018 in “Drug design, development and therapy”

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

research Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata

39 citations , November 2017 in “Journal of The American Academy of Dermatology”

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Multiplex Matrix Network Analysis of Protein Complexes in the Human TCR Signalosome

32 citations , August 2016 in “Science Signaling”

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , October 2014 in “Autoimmunity reviews”

Alopecia areata is caused by the immune system attacking hair follicles.

research Alopecia: Evaluation and Treatment

76 citations , July 2011 in “Clinical, Cosmetic and Investigational Dermatology”

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

research Prognostic Factors in Methylprednisolone Pulse Therapy for Alopecia Areata

27 citations , May 2011 in “Journal of dermatology”

Methylprednisolone pulse therapy works best for recent and specific types of severe alopecia areata.

research Alopecia Areata Update

244 citations , January 2010 in “Journal of the American Academy of Dermatology”

The document says current treatments for alopecia areata do not cure or prevent it, and it's hard to judge their effectiveness due to spontaneous remission and lack of studies.

research Intralesional Steroids for Alopecia Areata

36 citations , January 2010 in “International Journal of Trichology”

Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.

research Lymphocytes, Neuropeptides, And Genes Involved In Alopecia Areata

286 citations , August 2007 in “Journal of Clinical Investigation”

Alopecia areata is an autoimmune disease where T cells attack hair follicles.